WO1995002406A3 - Use of benzothiophenes and benzofurans for the treatment of inflammatory bowel disease and inflammation assay method - Google Patents

Use of benzothiophenes and benzofurans for the treatment of inflammatory bowel disease and inflammation assay method Download PDF

Info

Publication number
WO1995002406A3
WO1995002406A3 PCT/US1994/007240 US9407240W WO9502406A3 WO 1995002406 A3 WO1995002406 A3 WO 1995002406A3 US 9407240 W US9407240 W US 9407240W WO 9502406 A3 WO9502406 A3 WO 9502406A3
Authority
WO
WIPO (PCT)
Prior art keywords
benzothiophenes
benzofurans
inflammatory bowel
treatment
bowel disease
Prior art date
Application number
PCT/US1994/007240
Other languages
French (fr)
Other versions
WO1995002406A2 (en
Inventor
James Alan Dykens
Joseph Edwin Low
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Priority to EP94923904A priority Critical patent/EP0789569A2/en
Priority to JP7504574A priority patent/JPH09500130A/en
Priority to AU73961/94A priority patent/AU7396194A/en
Publication of WO1995002406A2 publication Critical patent/WO1995002406A2/en
Publication of WO1995002406A3 publication Critical patent/WO1995002406A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This instant invention is novel uses of known benzothiophenes or benzofurans and pharmaceutically acceptable salts thereof. Such compounds as 5-methoxy-3-(1-methylethoxy)-N-1H-tetrazol-5-ylbenzo[b]thiophene-2-carboxamide is used for treating inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. The instant invention is also an assay for noninvasively monitoring inflammation.
PCT/US1994/007240 1993-07-15 1994-07-11 Use of benzothiophenes and benzofurans for the treatment of inflammatory bowel disease and inflammation assay method WO1995002406A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP94923904A EP0789569A2 (en) 1993-07-15 1994-07-11 Use of benzothiophenes and benzofurans for the treatment of inflammatory bowel disease and inflammation assay method
JP7504574A JPH09500130A (en) 1993-07-15 1994-07-11 Benzothiophene and benzofuran as agents for use in the treatment of inflammatory bowel disease and method for assaying inflammation
AU73961/94A AU7396194A (en) 1993-07-15 1994-07-11 Use of benzothiophenes and benzofurans for the treatment of inflammatory bowel disease and inflammation assay method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9204593A 1993-07-15 1993-07-15
US08/092,045 1993-07-15

Publications (2)

Publication Number Publication Date
WO1995002406A2 WO1995002406A2 (en) 1995-01-26
WO1995002406A3 true WO1995002406A3 (en) 1995-04-27

Family

ID=22231123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/007240 WO1995002406A2 (en) 1993-07-15 1994-07-11 Use of benzothiophenes and benzofurans for the treatment of inflammatory bowel disease and inflammation assay method

Country Status (6)

Country Link
EP (1) EP0789569A2 (en)
JP (1) JPH09500130A (en)
AU (1) AU7396194A (en)
CA (1) CA2163542A1 (en)
MX (1) MX9405380A (en)
WO (1) WO1995002406A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1347963B1 (en) 2000-12-05 2004-08-25 F. Hoffmann-La Roche Ag Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
MXPA05013210A (en) * 2003-06-05 2006-03-09 Warner Lambert Co Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863923A (en) * 1988-07-01 1989-09-05 Eli Lilly And Company Method of inhibiting superoxide release

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863923A (en) * 1988-07-01 1989-09-05 Eli Lilly And Company Method of inhibiting superoxide release

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOW, J.E. ET AL: "GASTRIC CYTOPROTECTIVE EFFECTS OF CI-959 AGAINST THE EROSIVE EFFECT OF ETHANOL, INDOMETHACIN AND ASPIRIN", GASTROENTEROLOGY, vol. 104, no. 4, April 1993 (1993-04-01), pages A137 *

Also Published As

Publication number Publication date
MX9405380A (en) 1995-01-31
WO1995002406A2 (en) 1995-01-26
JPH09500130A (en) 1997-01-07
CA2163542A1 (en) 1995-01-26
AU7396194A (en) 1995-02-13
EP0789569A2 (en) 1997-08-20

Similar Documents

Publication Publication Date Title
EP0686203A4 (en) Compounds and methods for the diagnosis, treatment and prevention of diseases of cell death
EP0808324A4 (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
FR2739255B1 (en) PEST CONTROL COMPOSITION FOR THE TREATMENT AND PROTECTION OF PETS
WO1999063977A3 (en) Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone, triazolam and brotizolam for treating or preventing sleep disorders
CA2289717A1 (en) Novel therapy for constipation
FI941826A (en) Methods and compositions for the prevention and / or therapeutic treatment of organ hypofunction
GR3017691T3 (en) Oral composition for the treatment of inflammatory bowel diseases.
NO20010593L (en) Preparation and Procedure for the Treatment of Peyronie's Disease and Other Subdermal Plaque Manifestation Disorders
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
GB8900678D0 (en) Compositions for the prevention and medical treatment of parodonthopathy
WO1997003188A3 (en) Use of mp52 or mp121 for treating and preventing diseases of the nervous system
DE69613693T2 (en) 2-HETEROARYLALKENYL DERIVATIVES OF CYCLOPENTANO-HEPTANE (HEPTAEN) ACID AS A THERAPEUTIC AGENT FOR TREATING THE INCREASED EYE PRESSURE
AU4376396A (en) Use of andrographolide compounds to treat or prevent pathogenicity of diseases
IL126683A0 (en) Pharmaceutical composition and method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
WO1995002406A3 (en) Use of benzothiophenes and benzofurans for the treatment of inflammatory bowel disease and inflammation assay method
EP0992243A4 (en) Prophylactic/remedial agent
ZA991749B (en) Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy.
NO922531D0 (en) AGENT FOR THE PREVENTION AND TREATMENT OF FISH DISEASES
FR2786100B1 (en) NEW THERAPEUTIC APPLICATION OF NICERGOLIN
CA2158173A1 (en) Method of treating addictive behaviors
WO2001042205A3 (en) Treatment of inflammatory bowel disease with vitamin d compounds
DE69223455D1 (en) Prophylactic / therapeutic composition containing WS7622A for the prevention and treatment of dispersed intravascular coagulation, chronic, infectious respiratory diseases or chronic bronchitis
EP0687687A3 (en) Pharmaceutical compositions for prevention and treatment of blood coagulation disorders
AU4841296A (en) Diagnosis of and compositions and methods for the treatment of disease
ID20165A (en) USE OF ACID 2- (3,4-DIMETOXICINAMOIL) AMINOBENZOAT FOR MAKING MEDICINES FOR TREATMENT OR PREVENTION OF RESTENOSIS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP NZ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2163542

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994923904

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994923904

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994923904

Country of ref document: EP